Anja Manuel Purchases 1,000 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) Director Anja Manuel bought 1,000 shares of Hims & Hers Health stock in a transaction dated Thursday, November 14th. The stock was acquired at an average price of $24.50 per share, with a total value of $24,500.00. Following the purchase, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $122,500. This represents a 25.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

Anja Manuel also recently made the following trade(s):

• On Tuesday, November 12th, Anja Manuel acquired 4,000 shares of Hims & Hers Health stock. The stock was acquired at an average price of $26.94 per share, with a total value of $107,760.00.

Hims & Hers Health Trading Down 5.4 %

Shares of HIMS traded down $1.13 during midday trading on Friday, reaching $19.72. The stock had a trading volume of 13,139,313 shares, compared to its average volume of 9,171,635. The company’s 50-day moving average is $19.64 and its 200 day moving average is $18.78. The company has a market capitalization of $4.24 billion, a price-to-earnings ratio of 47.38 and a beta of 1.06. Hims & Hers Health, Inc. has a 12-month low of $7.40 and a 12-month high of $30.44.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s revenue was up 77.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.04) EPS. Research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

HIMS has been the subject of several recent research reports. Canaccord Genuity Group lifted their price target on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Piper Sandler reiterated a “neutral” rating and set a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. TD Cowen increased their price target on shares of Hims & Hers Health from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Needham & Company LLC began coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price on the stock. Finally, Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating in a research note on Thursday. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $21.21.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently bought and sold shares of HIMS. Nisa Investment Advisors LLC boosted its stake in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC boosted its position in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after buying an additional 3,507 shares during the period. CWM LLC grew its holdings in Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares during the last quarter. Van ECK Associates Corp purchased a new position in shares of Hims & Hers Health in the second quarter valued at about $111,000. Finally, Amalgamated Bank raised its stake in shares of Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.